Positive new and updated data from a phase I and pivotal phase II trial (ELM-1 and ELM-2), evaluating investigational odronextamab in patients with relapsed/refractory diffuse large B-cell lymphoma, were presented in an oral session at the 64th American Society of Hematology Annual Meeting and Exposition and will form the basis of planned submissions to regulatory authorities in 2023, including to FDA.
The National Comprehensive Cancer Network included circulating tumor DNA testing in their Clinical Practice Guidelines in Oncology for diffuse large B-cell lymphoma. This marks the first-ever inclusion of ctDNA-MRD testing in these guidelines, representing a significant advancement in lymphoma patient care.
